Page 53 - CIBERES-2015-eng

na Inactivada contra tuberculosis en base a una cepa modificada genéticamente”. 2013-16
Line 2: • Polimorfismos genómicos y transcriptómi- cos en M. tuberculosis complex y su significado en clínica. IP: Sofía Samper. Number of researchers: 10; FIS 12/1970, Instituto de Salud Carlos III. 2013-15. • Study of the impact of RD8 on the regulation of ESAT- 6 secretion in M. bovis and M. africanum.SecReg- ulTBC. REFBIO. 2013-14 • Antimicrobial resistance, virulence and new therapies in bacterial human path- ogens. REFBIO 2013-14 • Network: European refer-
ence laboratory network for tuberculosis (ERLTB-Net) - to strengthen TB diagnosis, drug susceptibility test- ing and coordination at European Union level. Ref: GRANT/2013/003. ECDC. Fecha inicio: 2014.
Line 3: • MM4TBMore Medicines for Tuberculosis. European Union FP7. 2011-14 • NAREB - Nanother- apeutics for antibiotic resistant emerging bacterial pathogens. European Union FP7. 2014-18 • SAF- 2013-48971-C2-2-R. Aplicaciones biomédicas de AS-48, una proteína con amplio espectro de actividad antimicrobiana. 2014-16.
Research Groups
Most relevant scientific articles
sPertini F., auDran r., ChaKour r., Karoui o., stein- er-MonarD v., thierry a.-C. et aL. Safety of human im- munisation with a live-attenuated Mycobacterium tuber- culosis vaccine: A randomised, double-blind, controlled phase I trial. The Lancet Respiratory Medicine. 2015;:-.
igLesias M.-J., Martín C.. Editorial commentary: Nonspe- cific beneficial effects of BCG vaccination in high-income countries, should we extend recommendation of BCG vac- cination?. Clinical Infectious Diseases. 2015;60(11):1620- 1621.
Broset e., Martín C., gonzaLo-asensio J.. Evolutionary landscape of the mycobacterium tuberculosis complex
Highlights
In 2015 we started the European project TBVAC H2020 “Advancing novel and promising TB vac- cine candidates from discovery to preclinical and early Clinical development” in collaboration with 40 International Universities and Research Centers. Safety and Immunogenicity of the first Clinical trial in human with MTBVAC in healthy adults in Laus- anne Switzerland, has been published in Decem- ber 2015 (Spertini et al Lancet Respir Med. 2015 Dec;3(12):953-62.). Excellent safety and strong im- munogenicity data, support advanced clinical devel- opment in high-burden tuberculosis endemic coun- tries. In September 2015 South African authorities have approved Phase 1b in neonates in South Africa.
In line 2, the analysis of the more transmitted strains in our population and monitoring these strains over time, including the genomic changes as marks of evolution, using different techniques has been done.
from the viewpoint of phoPR: Implications for virulence regulation and application to vaccine development. mBio. 2015;6(5):-.
BaiLo r., Bhatt a., ainsa J.a.. Lipid transport in Myco- bacterium tuberculosis and its implications in virulence and drug development. Biochemical Pharmacology. 2015;96(3):159-167.
MiLLan-Lou M.i., otaL i., MonForte M.L., vitoria M.a., re- viLLo M.J., Martín C. et aL. In Vivo IS6110 profile changes in a Mycobacterium tuberculosis strain as determined by tracking over 14 years. Journal of Clinical Microbiology. 2015;53(7):2359-2361.
We have studied tuberculosis and other mycobacte- ria disease in children. We have started using mass sequencing to detect resistance and phylogeny of the M. tuberculosis complex. We collaborated in the development for rapid techniques for detecting re- sistance to drugs of first and second line.
In line 3, we have progressed in the characterisation of the impact of efflux pumps in intrinsic drug re- sistance of M. tuberculosis against new candidate drugs in development, that have been identified by our European collaborators through phenotypic screenings. We have started the study of novel drug targets (implicated in the metabolism of nucleic acids and control of oxidative stress response) for developing new antituberculosis agents. We have identified several combinations of drugs that do not decrease their antimicrobial activity upon encapsu- lation on nanoparticles of diverse chemical origins.
Institution: Universidad de Zaragoza · Contact:Calle Pedro Cerbuna, 12. 50009 Zaragoza Tel.: 976 761 759 · E.mail: [email protected] · Website: http://[email protected]
CIBERES I Annual report 2015 I 53